{"title": "Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction", "doi": "10.1101/2020.02.27.20027557", "citation_id": "2020.02.27.20027557v1", "date": "2020-02-29", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.27.20027557", "abstract": "<p>The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.</p>", "twitter_description": "The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Clinical Trial\n\nChiCTR2000030055\n\n### Funding Statement\n\nNational Key R&D Program of China (2017YFB0202600), National Natural Science Foundation of China (91742109, 8152204, 31770978, 81773674, and 21877134), Taikang Insurance Group Co., Ltd and Beijing Taikang Yicai Foundation, and philanthropy donation from individuals. The funders had no roles in the design and execution of the study.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/29/2020.02.27.20027557.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.27.20027557v1", "access_rights": "restricted", "authors": ["Xiaoyan Liu", "Zhe Li", "Shuai Liu", "Zhanghua Chen", "Zhiyao Zhao", "Yi-you Huang", "Qingling Zhang", "Jun Wang", "Yinyi Shi", "Yanhui Xu", "Jing Sun", "Huifang Xian", "Rongli Fang", "Fan Bai", "Changxing Ou", "Bei Xiong", "Andrew M Lew", "Jun Cui", "Hui Huang", "Jincun Zhao", "Xuechuan Hong", "Yuxia Zhang", "Fulin Zhou", "Hai-Bin Luo"]}